iSpecimen Inc (NASDAQ: ISPC) is a life sciences marketplace company that connects researchers to human biospecimens, research subjects, and associated data through its proprietary iSpecimen Marketplace platform. Revenue is transactional, generated when researchers search, select, and purchase biospecimens and associated data from a network of laboratory and biobank suppliers, with the company acting as intermediary from inquiry to invoice. The platform ingests de-identified specimen and patient data from electronic medical records, laboratory information systems, and biobank inventory systems, harmonizing this data into a searchable dataset for research buyers. iSpecimen was founded to address the challenge of sourcing human biofluids, tissues, and living cells for life science research. During the year ended December 31, 2025, the company reduced monthly compensation costs by approximately 67% and technology costs by approximately 25% compared to FY2024, reflecting a sustained cost-reduction effort that began in 2023. The company is headquartered in the United States and operates a supply network that includes international suppliers, including sites previously active in Russia and Ukraine.

Revenue model

Transactional revenue from biospecimen procurement: researchers place orders through the iSpecimen Marketplace and the company fulfills those orders by sourcing specimens from its supplier network. Revenue is recognized on completed specimen transactions. A pre-judgment security order in active litigation required 15% of net revenue to be deposited in escrow, with only $13,000 deposited as of the filing date (10-K, filed 2026-04-01), indicating very low net revenue levels.

Products and services

iSpecimen Marketplace: a web-based platform allowing researchers to search de-identified healthcare data, filter by study inclusion and exclusion criteria, select available biospecimens from laboratory and biobank partners, request quotes, place orders, and track fulfillment. The platform also supports custom specimen collection requests when inventory is unavailable. Adjacencies under exploration include clinical trial patient recruitment, data licensing, and software-as-a-service (SaaS), per the FY2024 10-K.

Customers and end markets

Life science researchers at pharmaceutical, biotechnology, academic, and clinical research organizations who require human biospecimens for research and development. Demand is linked to research funding availability; the company noted in its FY2025 10-K that economic slowdowns and reduced research funding negatively affect specimen demand.

Value-chain role

Marketplace intermediary sitting between biospecimen suppliers (laboratories, biobanks, hospitals) and research buyers. The company does not own specimen inventory; it matches supply to demand, manages fulfillment logistics, and provides data harmonization and workflow tools to both sides of the transaction.

Geographic exposure

Primarily United States-based operations with an international supplier network. The company previously sourced from suppliers in Ukraine and Russia; as of December 31, 2025, Russian supply sites not under sanctions were accessible and Ukrainian sites had mostly reopened, though the company does not use Ukrainian suppliers as sole sources given ongoing war uncertainty (10-K, filed 2026-04-01).

Source: SEC 10-K, filed 2026-04-01

Industry: Services-Commercial Physical & Biological Research Peers: Better Therapeutics, Inc. Biotricity Inc MediXall Group, Inc. Healthcare Triangle Inc Healthlynked Corp iCoreConnect Inc. NantHealth, Inc.